Frankel Stanley 4

What Happened

• Stanley Frankel, a director of Precision BioSciences, had 21,000 restricted stock units (RSUs) vest on May 20, 2026. The Form 4 records an acquisition/conversion of 21,000 derivative units into common shares and a corresponding entry showing 21,000 shares at $0.00 (no cash reported).

Key Details

• Transaction date: May 20, 2026; Form 4 filed: May 22, 2026 (appears timely, two days after the vesting date).
• Reported activity: Exercise/conversion of derivative (code M) for 21,000 RSUs → 21,000 shares acquired; a matching line shows 21,000 shares at $0.00 as a disposition/conversion entry.
• Shares owned after the transaction: not specified in the materials provided.
• Footnotes: F1 — RSUs vested on May 20, 2026. F2 — each RSU converts to one share. F3 — RSUs were granted June 3, 2025 and vested on the earlier of June 3, 2026 or the day before the issuer’s next annual meeting, subject to continued service.
• Filing does not explain any tax withholding or share surrender; the $0.00 disposition line is recorded but no further detail is given.

Context

• This was an award/vesting event (RSUs converting to common stock), not an open-market purchase or sale. Such vesting is a routine compensation/retention event and does not necessarily signal the insider’s buying or selling sentiment. The filing shows conversion of derivative awards into shares rather than a cash transaction.